Stryker Q2 adjusted EPS beats estimates, narrows 2026 outlook
SYK•Drivers of the result
- Unit volume growth - The company said increased unit volume was the main driver of organic net sales growth in both MedSurg and Neurotechnology and Orthopaedics segments.
- Recovery from cyber incident - Stryker said progress in recovering from a cyber incident contributed to improved sales and earnings.
- Operational execution - The CEO cited disciplined operational execution and innovation as supporting improved performance.
Key figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 net sales | Slight Beat* | $6.60 bln | $6.58 bln (25 analysts) |
| Q2 adjusted EPS | Beat | $3.69 | $3.49 (24 analysts) |
| Q2 EPS | $3.30 |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".
Wall Street's median 12-month price target for Stryker Corp is $385.00, about 9.3% above its July 29 closing price of $352.25.
